摘要: |
Almost 1 in 4 driving licences with a medical notification has a notification related to treatment for diabetes. In 2014, this was equivalent to approximately 575,000 active licences for people treated with diabetes, of which 13% were Group 2 drivers (typically of lorries and/or buses). Recommendations from the Driver and Vehicle Licensing Agency (DVLA) on driving with diabetes have changed in recent years to reflect evidence of increased risks related to hypoglycaemia for certain categories of medicines. Drivers are likely to have their licence revoked after one severe hypoglycaemic event (for Group 2 drivers) or two events (for Group 1 drivers of cars, light vans and/or motorcycles). Yet the onus for safe driving remains with the individual, who is responsible for managing their condition irrespective of the extent of education they have had on how to prevent hypoglycaemia or options they have been offered by healthcare professionals to help minimise risk. Coupled with demands they may face when driving for work purposes, which can include long distances and hours, and a threat to their livelihood if their licence is revoked, it is unsurprising more people do not seek help. This report evaluates the evidence related to the prevalence and impact of hypoglycaemia for people with Type 2 Diabetes who drive and makes recommendations on how these people can be supported through better recording of hypoglycaemia, research, optimisation of medicine management, support and education. |